Zenith Drugs made an impressive entrance on the NSE SME, with its shares commencing trading at ₹110 each, marking a 39.24% increase from its issue price of ₹79. Known for their focus on affordable and high-quality generic medicines, the company had set its IPO price band between ₹75 to ₹79. The IPO comprised lots of 1,600 shares, allowing investors to bid for a minimum of 1,600 shares or in multiples, leading to a strong debut on the market.
Zenith Drugs based in Indore is dedicated to producing affordable, high-quality generic medicines. The company, adhering to WHO-GMP standards and ISO 9001:2015, offers a variety of formulations. They focus on growth, technology, and service, aiming to be a global pharmaceutical leader. With strategic investments, the company aims for continuous improvement to meet healthcare needs.
Zenith Drugs’ IPO aims to fund new machinery (INR 1,074.82 lakhs), upgrade existing manufacturing facilities (INR 210.59 lakhs), and bolster working capital by INR 1,200 lakhs. Remaining funds will support general corporate purposes, including strategic initiatives, partnerships, and marketing efforts.